584 related articles for article (PubMed ID: 1652797)
1. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
[TBL] [Abstract][Full Text] [Related]
2. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
[TBL] [Abstract][Full Text] [Related]
3. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
4. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
Tam SW; Liu-Chen LY
J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
[TBL] [Abstract][Full Text] [Related]
5. Covalent labeling of mu opioid binding site by [3H]beta-funaltrexamine.
Liu-Chen LY; Phillips CA
Mol Pharmacol; 1987 Sep; 32(3):321-9. PubMed ID: 2823089
[TBL] [Abstract][Full Text] [Related]
6. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.
Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319
[TBL] [Abstract][Full Text] [Related]
7. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
8. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor.
Liu-Chen LY; Li SX; Tallarida RJ
Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672
[TBL] [Abstract][Full Text] [Related]
9. Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1995 Mar; 272(3):1135-40. PubMed ID: 7891326
[TBL] [Abstract][Full Text] [Related]
10. Effects of intracerebroventricular administration of beta-funaltrexamine on [3H]DAMGO binding to rat brain sections.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1993 Oct; 267(1):506-14. PubMed ID: 8229781
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
12. A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site.
Rothman RB; Bowen WD; Herkenham M; Jacobson AE; Rice KC; Pert CB
Mol Pharmacol; 1985 Mar; 27(3):399-409. PubMed ID: 2579319
[TBL] [Abstract][Full Text] [Related]
13. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
14. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.
Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A
Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046
[TBL] [Abstract][Full Text] [Related]
15. Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography.
Morris BJ; Millan MJ; Herz A
J Pharmacol Exp Ther; 1988 Nov; 247(2):729-36. PubMed ID: 2846828
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sites.
Rothman RB; Bykov V; Long JB; Brady LS; Jacobson AE; Rice KC; Holaday JW
Eur J Pharmacol; 1989 Jan; 160(1):71-82. PubMed ID: 2540993
[TBL] [Abstract][Full Text] [Related]
17. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
18. Evidence for mu opioid receptor mediation of enkephalin-induced electroencephalographic seizures.
Tortella FC; Robles L; Mosberg HI
J Pharmacol Exp Ther; 1987 Feb; 240(2):571-7. PubMed ID: 3027318
[TBL] [Abstract][Full Text] [Related]
19. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
Locke KW; Holtzman SG
J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
[TBL] [Abstract][Full Text] [Related]
20. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system.
Tao R; Auerbach SB
J Pharmacol Exp Ther; 2002 Nov; 303(2):549-56. PubMed ID: 12388635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
